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Abstract
Background: The emergence of new therapies for the treatment of rheumatoid arthritis (RA), the paucity of
head-to-head studies, and the heterogeneous nature of responses to current biologics highlight the need for the
identification of prognostic factors for treatment response and retention in clinical practice. Prognostic factors for
patient retention have not been explored thoroughly despite data for abatacept and other biologics being available
from national registries. Real-world data from the ACTION study may supplement the findings of randomized
controlled trials and show how abatacept is used in clinical practice. The aim of this interim analysis was to identify
prognostic factors for abatacept retention in patients with RA who received at least one prior biologic agent.
Methods: A large, international, non-interventional cohort of patients with moderate-to-severe RA who initiated
intravenous abatacept in Canada and Europe (May 2008–January 2011) enrolled in the ACTION study. Potential
prognostic factors for retention in this interim analysis (data cut-off February 2012; including patients from Canada,
Germany, Greece, and Italy) were baseline demographics and disease characteristics, medical history, and previous and
concomitant medication. Clinically relevant variables with p≤ 0.20 in univariate analysis and no collinearity were
entered into a Cox proportional hazards regression model, adjusted for clustered data. Variables with p≤ 0.10 were
retained in the final model (backward selection).
Results: The multivariate model included 834 patients. Anti-cyclic citrullinated peptide (CCP) antibody positivity (hazard
ratio [95 % confidence interval]: 0.55 [0.40, 0.75], p < 0.001), failure of <2 prior anti-tumor necrosis factors (TNFs) (0.71
[0.56, 0.90], p = 0.005 versus ≥2 prior anti-TNFs), and cardiovascular comorbidity at abatacept initiation (0.48 [0.28, 0.83],
p = 0.009) were associated with lower risk of abatacept discontinuation. Patients in Greece and Italy were less likely to
discontinue abatacept than patients in Germany and Canada (Greece: 0.30 [0.16, 0.58]; Italy: 0.50 [0.33, 0.76]; Canada:
1.04 [0.78, 1.40], p < 0.001 versus Germany).
Conclusions: Real-world prognostic factors for abatacept retention include anti-CCP positivity and fewer prior anti-TNF
failures. Differences in retention rates between countries may reflect differences in healthcare systems. The finding that
abatacept has potential advantages in patients with cardiovascular comorbidities needs to be confirmed in further
research.
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Background
Abatacept is a fully humanized fusion protein that acts as
a selective T-cell co-stimulation modulator. It is approved
globally for the treatment of moderate-to-severe rheuma-
toid arthritis (RA) in patients with an inadequate response
to one or more disease-modifying anti-rheumatic drugs
(DMARDs; including methotrexate [MTX] or an anti-
tumor necrosis factor [TNF]) [1–4]. In Canada, abatacept
can also be used in combination with MTX for the treat-
ment of moderate-to-severe RA in patients who are
MTX-naïve [1–4]. Abatacept is available in subcutane-
ous and intravenous (IV) formulations [1–4], and a
favorable efficacy and safety profile has been demon-
strated in randomized controlled trials [5, 6]. IV aba-
tacept received regulatory approval for the treatment
of RA in 2006 in Canada and in 2007 in Europe. AC-
TION (AbataCepT In rOutiNe clinical practice) is a
large, real-world, prospective, observational cohort
study of patients with RA from Europe and Canada
who were receiving IV abatacept and were followed
for a maximum of 2 years. Results from a 6-month
interim analysis of the ACTION study suggest that
abatacept is an effective and well-tolerated treatment
option in patients with RA [7].
The emergence of new therapies for the treatment
of RA, the paucity of head-to-head studies, and the
heterogeneous nature of responses to current bio-
logics highlight the need for the identification of
prognostic factors for treatment response and reten-
tion in clinical practice. The identification of prognos-
tic factors may support individualized treatment
strategies and could aid physicians in making in-
formed therapeutic decisions [8].
Real-world studies may include patients with a wide
range of disease activity levels and encompass re-
gional variations in treatment, and can therefore sup-
plement the findings of randomized controlled trials
with strict inclusion and exclusion criteria [9]. Al-
though some studies have identified prognostic factors for
response to abatacept, few have been confirmed [10]. In
the French Orencia and Rheumatoid Arthritis (ORA)
registry, positivity for anti-cyclic citrullinated peptide
(CCP) antibodies was associated with European League
Against Rheumatism (EULAR) response in a multivariate
analysis, after adjustment for Disease Activity Score
(DAS)28 [11]. In an Italian study of 32 patients with RA
who had been treated with abatacept, low levels of CD4 +
CD28− and CD8 +CD28− T cells were associated with a
greater likelihood of achieving remission at 6 months [12].
Treatment discontinuation can result from safety con-
cerns or a lack of efficacy, but prognostic factors for pa-
tient retention have not been explored thoroughly despite
data for abatacept and other biologics being available from
national registries. In patients within the ORA registry,
anti-CCP positivity occurred more frequently in patients
who had continued abatacept treatment after 6 months,
compared with patients who had discontinued abatacept
(72.5 % versus 62.4 %, p = 0.02) [11]. In the Swedish
Rheumatology register, 6-month abatacept retention rates
were higher in patients who were biologic naïve compared
with patients who had received 1 or ≥2 previous biologics
(94 % versus 78 % and 77 %, respectively) [13]. In a pooled
analysis of eight European RA registries, abatacept reten-
tion was strongly influenced by the number of previous bi-
ologics. Compared with patients who had not previously
received biologic agents, retention was lower in patients
who had received prior biologics (p < 0.01) [14].
This article reports prognostic factors for abatacept re-
tention in patients with RA who had failed at least one
prior biologic agent which were identified in an interim
analysis from the international, non-interventional AC-
TION cohort study.
Methods
Study design and patient population
ACTION was a non-interventional, international, mul-
ticenter, cohort study that evaluated retention and
effectiveness in patients with RA who had initiated IV
abatacept in Europe (according to the abatacept Sum-
mary of Product Characteristics) and Canada (accord-
ing to the abatacept Product Monograph) [2–4].
Patients were enrolled prospectively, within 3 months
of abatacept initiation, between May 2008 and January
2011, and were followed for up to 2 years or, if the pa-
tient discontinued abatacept treatment before the 2-
year endpoint, for up to 6 months after abatacept dis-
continuation. A detailed description of the ACTION
study design has been reported previously in the con-
text of a 6-month interim analysis [7, 15].
The study enrolled adult patients who were abata-
cept naïve, with established moderate-to-severe RA
according to American College of Rheumatology re-
vised criteria (1987) [16]. ACTION was conducted in
accordance with the Declaration of Helsinki [17], the
International Conference on Harmonization Good
Clinical Practice Guidelines [18], and the Good Epi-
demiological Practice Guideline [19]. The study proto-
col and patient enrollment were approved by local
ethics committees and regulatory agencies in accord-
ance with each country’s requirements (first approval
received on 31 January 2008, in Munich, Germany;
Additional file 1: Table S1). Enrolled patients provided
written informed consent.
Here we present an interim analysis of the AC-
TION study in patients who were treated in four
countries (Canada, Germany, Greece, and Italy). All
data received up to February 2012 were considered.
The analysis included only patients who had received at
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least one prior biologic agent (the number of patients who
had received no prior biologics was insufficient to build a
robust model) and who had a baseline clinical assessment
no later than 8 days after the first administration of abata-
cept [20].
Definition of abatacept exposure
The dates of first and last abatacept infusions were
collected, and abatacept discontinuation and reasons
for discontinuation were reported by the rheumatolo-
gist at any follow-up visit. Exposure to abatacept was
defined as the difference between the first and last date of
abatacept infusion, plus 30 days. Patients who did not dis-
continue abatacept were censored at the time of last avail-
able data.
Prognostic factors of retention
Data concerning potential prognostic factors, including
known risk factors and clinically relevant variables, were
collected at abatacept initiation. Continuous and catego-
rized variables were considered in this analysis. Catego-
rizations were based on validated cut-offs when
available or on clinical expertise, previous literature, or
descriptive statistics such as medians or quartiles.
Sociodemographic variables were: country, age (con-
tinuous and <65 years, ≥65 years), sex, and body mass
index (continuous and <25 kg/m2 [underweight/normal],
25– < 30 kg/m2 [overweight], 30– < 35 kg/m2 [obese
class I], and ≥35 kg/m2 [obese class II/III]) [21]. Disease
characteristics considered were: disease duration (continu-
ous and ≤2 years, 3–5 years, 6–10 years, and >10 years),
tender joint count (continuous out of a total score of 28),
swollen joint count (continuous out of a total score of 28),
C-reactive protein (CRP) quartile (<4 mg/L, 4– < 10 mg/L,
10– < 26 mg/L, and ≥26 mg/L), patient global assessment
(continuous and based on median), physician global assess-
ment (continuous and based on median), pain (continuous
and based on median), DAS28 (erythrocyte sedimentation
rate or CRP) (continuous and remission or low DAS [≤3.2],
moderate DAS [>3.2–5.1], and high DAS [>5.1]), calculated
Clinical Disease Activity Index (continuous and remission,
low or moderate DAS [≤22] and high DAS [>22]), radio-
graphic erosion, rheumatoid factor (RF) status, anti-CCP
status, and RF and anti-CCP double-positive status. RF and
anti-CCP peptide antibody status were based on the as-
sessment at abatacept initiation or any assessment made
previously. Comorbidity data (including cardiovascular co-
morbidity) were collected by assessment of medical history
at abatacept initiation and were classified by System Organ
Class (SOC) as per the Medical Dictionary for Regulatory
Activities. All SOCs were described and considered.
Also considered were: number of prior conventional
(c)DMARDs (0–3, >3), number of prior anti-TNF
agents (<2, ≥2), type of biologic agent received before
abatacept (anti-TNF, other mechanism of action), and
reason for discontinuation of last biologic agent (in-
tolerance, primary inefficacy, secondary inefficacy, im-
provement in disease, and other reasons pooled
together). Final considerations were: abatacept treat-
ment pattern at initiation (monotherapy, combination
with MTX, combination with other cDMARDs), pre-
scription for MTX at initiation, and corticosteroid use
before and at abatacept initiation (no corticosteroids,
continuous use of corticosteroids, corticosteroids stopped
at abatacept initiation, corticosteroids introduced at abata-
cept initiation).
Statistical analysis
Abatacept retention rates and 95 % confidence intervals
(CI) were described using Kaplan–Meier estimators. Over-
all retention rate and discontinuation for inefficacy and in-
tolerance were presented at 12 months. Descriptive analysis
was performed for all potential prognostic factors. All po-
tential prognostic factors were tested in univariate analysis.
For variables in which the categories ‘not available’ or ‘not
done’ were predefined, univariate analyses were performed
with and without consideration of this category; to be con-
sidered in the multivariate model both analyses were re-
quired to show consistent significant results. Clinically
relevant variables, known risk factors, and prognostic
factors with p ≤ 0.20 and no collinearity (two variables
were collinear if p < 0.05 and V-Cramer >0.5) were
retained in the multivariate model. Known risk factors
at treatment initiation, such as infections and infesta-
tions, chronic obstructive pulmonary disease (COPD),
diabetes mellitus, and tobacco use, were considered in
the multivariate model regardless of results in the
univariate analysis. Prognostic factors of abatacept re-
tention were identified over the whole period until
the data cut-off (February 2012) by multivariate ana-
lysis using a Cox proportional hazards model with
clustered data (sandwich method) to account for de-
pendence among patients from a single site. Prognos-
tic factors with p > 0.10 were removed by backward
selection. Interactions between the retained prognostic
factors were tested and included in the final model if
significant (p < 0.10). Univariate analyses were re-run
for the final patient sample included in the final
multivariate model. Results were presented as hazard
ratios (HRs) with 95 % CIs and p-values. An HR >1
indicates higher likelihood of abatacept discontinu-
ation, while an HR <1 indicates a lower likelihood of
abatacept discontinuation. HRs are significant when
the 95 % CIs do not overlap 1. A sensitivity analysis
was performed, including all variables that were sig-
nificant in the univariate analysis with no variable
selection in the multivariate step.
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Results
Patient population
Between May 2008 and January 2011, 1138 patients
were enrolled in the ACTION study, 999 (87.8 %) of
whom were enrolled in Canada, Germany, Greece,
and Italy. A total of 865/999 (86.6 %) patients had re-
ceived at least one prior biologic agent. Patient base-
line demographic and disease characteristics and
comorbidities are shown in Table 1. Mean (standard
deviation [SD]) age was 56.5 (12.1) years, 83.1 % of pa-
tients were women, mean (SD) RA duration was 11.4 (8.7)
years (n = 842), 68.7 % were RF positive (n = 719 with
available data), and 64.5 % were anti-CCP positive (n = 456
with available data). Previous and concomitant treatments
for the overall analysis population are shown in Table 2.
Patients received a mean (SD) of 2.9 (1.5) prior cDMARDs,
with 283/865 (32.7 %) patients having received more than
three prior cDMARDs. An anti-TNF was the most fre-
quent type of last biologic agent received prior to abatacept
initiation (717/851 patients [84.3 %]) and 429/865 (49.6 %)
patients had received at least two prior anti-TNF agents.
The mean (SD) cumulative duration of the last biologic
agent was 18.9 (22.2) months (n = 801). Secondary ineffi-
cacy (loss of efficacy after initial response) was the most
common reason for discontinuation of the last biologic
(400/847 [47.2 %] patients). Abatacept was most frequently
initiated in combination with MTX (with or without other
cDMARDs; 483/865 [55.8 %] patients). In patients who
started or continued treatment with corticosteroids at aba-
tacept initiation, median (SD) corticosteroid dose was 8.73
(11.62) mg/day (n = 645).
Further analysis of baseline data revealed that most
characteristics were broadly comparable across the
countries assessed. However, some differences be-
tween countries were observed in terms of patient
demographics, disease characteristics, and previous
and concomitant therapies, as highlighted in the sup-
plementary information (Additional file 2: Table S2).
In a post hoc analysis, socio-demographics, disease
characteristics and comorbidities at abatacept initi-
ation were compared in patients who were anti-CCP
antibody seropositive versus seronegative. This ana-
lysis included all patients enrolled in ACTION be-
tween May 2008 and January 2011 who had received
at least one prior biologic agent. Patients who were
seropositive versus seronegative (n = 472 and n = 253, re-
spectively) had lower mean (SD) body weight (74.0 [16.6]
vs 77.2 [17.8] kg, p = 0.014) and body mass index (26.9 [5.3]
vs 28.5 [6.0] kg/m2, p = 0.001), longer RA duration (12.1
[8.9] vs 10.9 [9.5] years, p = 0.018) and more severe disease
(erythrocyte sedimentation rate: 37.5 [24.1] vs 30.1 [23.8]
mm/h, p < 0.001; radiographic erosion: 74.9 % vs 59.5 %, p
< 0.001). Concomitant treatments at abatacept initiation
were similar for patients who were seropositive versus
seronegative except for a numerically higher percentage of
patients with anti-CCP seropositivity who received con-
comitant corticosteroids (77.3 % vs 71.1 %, p = 0.072).
Retention rate
The overall retention rate over 12 months is shown in Fig. 1.
The retention rate (95 % CI) was 88.0 % (85.6, 90.1) at
6 months and 69.9 % (66.5, 73.0) at 12 months. The overall
retention rates (95 % CI) per country at 6 and 12 months,
respectively, were 96.8 % (90.4, 99.0) and 87.7 % (78.1, 93.2)
in Greece, 90.4 % (85.5, 93.7) and 80.3 % (74.1, 85.1) in
Italy, 89.2 % (83.3, 93.2) and 64.6 % (56.4, 71.8) in Canada,
and 83.6 % (79.3, 87.1) and 61.3 % (55.9, 66.3) in Germany.
Over 12 months, 21.2 % of patients discontinued aba-
tacept because of inefficacy (EULAR response) and 6.8 %
discontinued because of intolerance.
Univariate analysis
Known risk factors of COPD, diabetes mellitus, tobacco
use, and infection or infestation were proposed in the
model even though they were not significant. Based on
univariate analyses, 13 variables were eligible to enter
the multivariate model (p ≤ 0.20; Fig. 2). Among them,
two variables (RF and anti-CCP double positivity, and
concomitant MTX) were not entered into the multivari-
ate model due to collinearity with other prognostic
variables.
Multivariate analysis
Overall, 834/865 (96.4 %) patients were considered in
the multivariate model (Fig. 3). Patients had a signifi-
cantly lower risk of abatacept discontinuation if they
were anti-CCP positive (HR [95 % CI]: 0.55 [0.40,
0.75], p < 0.001), had failed <2 anti-TNF agents (0.71
[0.56, 0.90] versus ≥2 anti-TNF agents, p = 0.005), or
had a cardiovascular comorbidity at abatacept initi-
ation (0.48 [0.28, 0.83], p = 0.009). Patients in Greece
and Italy were less likely to discontinue abatacept than pa-
tients in Germany and Canada (HR [95 % CI] versus
Germany: 0.30 [0.16, 0.58] for Greece, 0.50 [0.33, 0.76] for
Italy, 1.04 [0.78, 1.40] for Canada, p < 0.001). No signifi-
cant interaction was found across prognostic factors. CRP
level at baseline, RF status at baseline, and type of previous
anti-TNF failure were significant in the univariate analysis
(p < 0.05) but were no longer significant in the multivari-
ate analysis. Abatacept treatment pattern at initiation
(monotherapy, combination with MTX or combination
with other cDMARDs) was entered into the multivariate
model but was not found to be significant. No effect was
observed in either univariate or multivariate analyses for
infection at initiation or disease duration. The sensitivity
analysis, including all variables that were significant in the
univariate analysis with no variable selection in the multi-
variate step, was consistent.
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Table 1 Baseline demographics, disease characteristics and
comorbidities (analysis population)
Characteristic N = 865
Demographics
Age N = 865
Mean (SD), years 56.5 (12.1)
<65 years, n (%) 615 (71.1)
≥65 years, n (%) 250 (28.9)
Body mass indexa N = 818
Mean (SD), kg/m2 27.5 (5.8)
<25 kg/m2, n (%) 310 (37.9)
25– < 30 kg/m2, n (%) 275 (33.6)
30– < 35 kg/m2, n (%) 154 (18.8)
≥35 kg/m2, n (%) 79 (9.7)
Sex N = 865
Men, n (%) 146 (16.9)
Women, n (%) 719 (83.1)
Country N = 865
Canada, n (%) 163 (18.8)
Germany, n (%) 370 (42.8)
Greece, n (%) 110 (12.7)
Italy, n (%) 222 (25.7)
Disease characteristics
RA duration N = 842
Mean (SD), years 11.4 (8.7)
≤2 years, n (%) 83 (9.9)
3–5 years, n (%) 169 (20.1)
6–10 years, n (%) 224 (26.6)
>10 years, n (%) 366 (43.5)
Tender joint count/28 N = 848
Mean (SD) 11.4 (7.3)
Swollen joint count/28 N = 858
Mean (SD) 7.9 (5.9)
HAQ-DI N = 796
<1.50, n (%) 332 (41.7)
≥1.50, n (%) 464 (58.3)
DAS28 (ESR, otherwise CRP) N = 793
Remission or LDAS (≤3.2), n (%) 24 (3.0)
MDAS (>3.2–5.1), n (%) 203 (25.6)
HDAS (>5.1), n (%) 440 (55.5)
Not done, n (%) 126 (15.9)
Table 1 Baseline demographics, disease characteristics and
comorbidities (analysis population) (Continued)
CDAI (calculated) N = 865
Remission, LDAS, or MDAS (≤22), n (%) 196 (22.7)
HDAS (>22), n (%) 568 (65.7)
Missing, n (%) 101 (11.7)
Radiographic erosion (presence) N = 750
No, n (%) 218 (29.1)
Yes, n (%) 532 (70.9)
CRP N = 865
<4 mg/L, n (%) 224 (25.9)
4– < 10 mg/L, n (%) 172 (19.9)
10– < 26 mg/L, n (%) 204 (23.6)
≥26 mg/L, n (%) 182 (21.0)
Not done, n (%) 83 (9.6)
RF status N = 852
Negative, n (%) 225 (26.4)
Positive, n (%) 494 (58.0)
Not available, n (%) 133 (15.6)
Anti-CCP status N = 834
Negative, n (%) 162 (19.4)
Positive, n (%) 294 (35.3)
Not available, n (%) 378 (45.3)
Comorbidities
Cardiovascular disorders N = 865
No, n (%) 807 (93.3)
Yes, n (%) 58 (6.7)
Cardiac arrhythmia, n (%) 22 (2.5)
Cardiac valve disorder, n (%) 9 (1.0)
Coronary artery disorder, n (%) 23 (2.7)
Heart failure, n (%) 15 (1.7)
Myocardial disorder, n (%) 2 (0.2)
COPD N = 865
No, n (%) 803 (92.8)
Yes, n (%) 62 (7.2)
Diabetes mellitus N = 865
No, n (%) 753 (87.1)
Yes, n (%) 112 (12.9)
Tobacco use N = 865
No, n (%) 757 (87.5)
Yes, n (%) 108 (12.5)
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Discussion
This is the first international, prospective study to evalu-
ate the prognostic factors for abatacept retention in a
real-world setting in patients with RA who had received
at least one prior biologic agent. In this interim analysis,
the 6- and 12-month abatacept retention rates were
88.0 % and 69.9 %, respectively. Abatacept retention
rates in ACTION were numerically within the range re-
ported in other published studies [11, 13, 22]. The 12-
month retention rates for abatacept were within the
range of those reported for tocilizumab [22–25] and for
anti-TNFs [26].
Here, we report predictive factors for abatacept reten-
tion at 12 months identified from a cohort of patients
from the ACTION study who had received at least one
prior biologic agent: anti-CCP positivity, failing <2 prior
anti-TNF agents, and cardiovascular comorbidity at initi-
ation were associated with higher retention. Differences
in retention between some countries were also observed.
The percentage of patients receiving abatacept as mono-
therapy in this study (23.2 %) was broadly consistent
with that observed in biologic registries (approximately
30 %) [27].
In this study, anti-CCP positivity was associated
with improved abatacept retention, compared with
anti-CCP negative status. In addition, RF seropositiv-
ity was significant in the univariate analysis but not
in the multivariate analysis. Anti-CCP positivity has
previously been shown to be a predictor of clinical
response to abatacept in patients with RA [11, 28].
The mechanisms underlying this association remain to be
further elucidated, although some initial findings suggest
that the very early effect of abatacept on T-cell modulation
is an important mechanism of action in patients with anti-
CCP positivity [29]. In the present study, patients with ex-
posure to at least two prior anti-TNFs were more likely to
discontinue abatacept than patients with exposure <2 prior
anti-TNFs. Patients with prior exposure to multiple anti-
TNFs are likely to have advanced RA and may find it diffi-
cult to benefit from any therapy; furthermore, previous
studies have shown that no or low prior exposure to bio-
logic agents is associated with longer drug survival in pa-
tients receiving tocilizumab or anti-TNFs [14, 23, 30]. The
reason for discontinuation of the last biologic agent prior
to abatacept initiation was a significant predictor of abata-
cept retention in the univariate but not the multivariate
analysis. In a subgroup analysis of the ATTAIN (Abatacept
Table 1 Baseline demographics, disease characteristics and
comorbidities (analysis population) (Continued)
Infections and infestations N = 865
No, n (%) 809 (93.5)
Yes, n (%) 56 (6.5)
Category in italics is the reference for univariate and multivariate analyses
The analysis population included patients treated in Canada, Germany,
Greece, and Italy who had received at least one prior biologic agent and
had a baseline clinical assessment no later than 8 days after the first
administration of abatacept
CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP
C-reactive protein, DAS Disease Activity Score, ESR erythrocyte sedimentation
rate, HAQ-DI Health Assessment Questionnaire-Disability Index, HDAS high
Disease Activity Score, LDAS low Disease Activity Score, MDAS moderate
Disease Activity Score, RA rheumatoid arthritis, RF rheumatoid factor,
SD standard deviation
aWorld Health Organization body mass index classification: underweight/
normal if <25 kg/m2, overweight if 25– < 30 kg/m2, obese class I if 30– <
35 kg/m2, and obese class II/III if ≥35 kg/m2 [21]
Table 2 Previous and concomitant medications (analysis
population)
Treatment parameter N = 865
Previous treatments
Number of prior DMARDs N = 865
0–3, n (%) 582 (67.3)
>3, n (%) 283 (32.7)
Number of prior anti-TNF agents N = 865
≥2, n (%) 429 (49.6)
<2, n (%) 436 (50.4)
Type of biologic agent N = 851
Other MOA, n (%) 134 (15.8)
Anti-TNF agent 717 (84.3)
Reason for discontinuation of last biologic N = 847
Intolerance, n (%) 190 (22.4)
Primary inefficacy, n (%)a 203 (24.0)
Secondary inefficacy, n (%)† 400 (47.2)
Major improvement + other reasons, n (%) 54 (6.4)
Concomitant therapies
Abatacept treatment pattern at initiation N = 865
Monotherapy, n (%) 201 (23.2)
Combination with MTX (± other DMARDs), n (%) 483 (55.8)
Combination with other DMARDs, n (%) 181 (20.9)
Corticosteroid treatment pattern at abatacept initiation
(versus before initiation)‡
N = 865
No corticosteroids, n (%) 202 (25.4)
Continuous use of corticosteroids, n (%) 491 (56.8)
Stop corticosteroid use, n (%) 18 (2.1)
Introduction of corticosteroids, n (%) 154 (17.8)
Category in italics is the reference for univariate and multivariate analyses
The analysis population included patients treated in Canada, Germany, Greece,
and Italy who had received at least one prior biologic agent and had a
baseline clinical assessment no later than 8 days after the first administration
of abatacept. Patient population includes 17 patients who did not receive
prior treatment with an anti-TNF agent but a biologic agent with
another MOA
DMARD disease-modifying anti-rheumatic drug, MOA mechanism of action,
MTX methotrexate, TNF tumor necrosis factor
aFailure to respond; †Loss of efficacy after initial response. ‡Mean (standard
deviation) corticosteroid dose was 8.73 (11.62) mg/day in patients who
continued use of corticosteroids or who started corticosteroids at abatacept
initiation (n = 645)
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Trial in Treatment of Anti-TNF INadequate responders)
trial, the reason for prior anti-TNF failure was not associ-
ated with differences in the efficacy of abatacept over
6 months [31].
Cardiovascular comorbidity at initiation (including car-
diac arrhythmia, cardiac valve disorders, coronary artery
disorders, heart failure, and myocardial disorders) was as-
sociated with a decreased risk of abatacept discontinuation
compared with not having cardiovascular comorbidity.
The long-term safety profile of abatacept is well estab-
lished in RA [32]. Abatacept does not have any special
warnings or contraindications in patients with cardiovas-
cular diseases. In contrast, adalimumab, certolizumab
pegol, golimumab and infliximab are contraindicated
in patients with moderate-to-severe heart failure (New
York Heart Association class III/IV) [33–36] and eta-
nercept has a special warning in patients with con-
gestive heart failure [37]; this may result in limited
options for switching treatment in patients with a his-
tory of cardiovascular comorbidity. Channeling may
have been introduced at abatacept initiation and co-
morbidities may have been underreported.
Differences in retention were observed between
countries in the multivariate analysis. Patients in
Greece and Italy were less likely to discontinue aba-
tacept than patients in Germany and Canada; these
differences in abatacept retention may represent dif-
ferences in patient populations and disease charac-
teristics, access to biologic agents, and national
guidelines for the management of RA. Although cov-
ering other European countries, country was found
to impact abatacept retention in a pooled analysis of
9 European registries [38, 39]. Baseline demographics
and disease characteristics were broadly comparable
across the countries included in this analysis, al-
though patients in Canada had higher swollen joint
counts and were less likely to exhibit radiographic
erosion than patients in Germany, Italy, and Greece.
Patients in Italy were less likely to have received ≥2
prior biologic agents compared with patients in the
other countries assessed, and rates of concomitant
corticosteroid use differed markedly between coun-
tries (48.5 % in Canada compared with 69.1 %,
78.8 %, and 85.1 % in Greece, Italy, and Germany,
respectively). In addition, several studies have re-
ported a lower incidence and prevalence of RA, as
well as disease activity, in southern European Union
(EU) countries versus northern EU countries [40, 41]. Ac-
cess to biologic agents may be related to gross domestic
product per capita and healthcare system structure, in-
cluding the number of rheumatologists per inhabitant
[38, 42, 43]. Treatment guidance for the management of
RA is available in most countries and may have been devel-
oped taking into account gross domestic product and dis-
ease parameters (e.g. disease activity, poor prognostic
factors) [44]. Finally, patient management is also dependent
on the type of practice (evidence-based versus routine prac-
tice). Together, these elements may partly explain differ-
ences in retention between countries, independently of
patient characteristics. However, such detailed information
was not specifically collected and is probably aggregated in
the variable ‘country’, including influence of genetic back-
ground and environmental factors.
The limitations of this study are similar to other
studies using uncontrolled, real-world data. There was
no active comparator in this study and there are few
examples of real-world data comparing abatacept with
other biologic agents, or comparing other biologic
agents. Owing to the real-world design of ACTION, a
selection bias based on disease severity or adverse
events is plausible. To minimize patient selection bias,
participating physicians enrolled subsequent patients
who were eligible as per the inclusion and exclusion
criteria. To ensure that ACTION did not interfere
with a physician’s routine clinical practice, the deci-
sion to treat a patient with abatacept was made prior
Fig. 1 Retention rate over 12 months of abatacept treatment
(analysis population). The retention rate estimate and 95 % CIs were
computed using the Kaplan–Meier method. An event was defined
as a discontinuation reported by the physician at any follow-up visit;
patients who did not reach the considered time point were censored at
the date of last data available; patients with only baseline data
were considered as censored at first infusion date. The analysis
population included patients treated in Canada, Germany, Greece, and
Italy who had received at least one prior biologic agent and had a
baseline clinical assessment no later than 8 days after the first
administration of abatacept. CI, confidence interval
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to enrollment in the study. A process of random se-
lection of study investigators from a comprehensive
list of rheumatologists was used to obtain a geograph-
ically balanced group of investigators in each country
who were representative of rheumatologists who treat
patients with IV biologics.
This analysis of patients from the ACTION study
included a large number of patients in an inter-
national real-life setting (n = 865), which permitted in-
clusion of a comprehensive list of all relevant
prognostic factors. Most previous studies of abatacept
in clinical practice have explored only national regis-
tries from single countries [11, 22, 45]. As this was
an interim analysis, further analyses are warranted to
confirm these findings.
Although many studies have identified predictive fac-
tors of clinical response to biologic agents, few have
been confirmed, in particular for abatacept [10]. Even
fewer studies have identified prognostic factors of abata-
cept retention. Similar trends were found in ACTION
and in the pooled analysis of 9 European registries [39].
Given the range of biologic agents now available for the
treatment of RA, the identification of patients who will
benefit from a specific therapy is of interest and may aid
realistic cost-effectiveness estimates. Therefore, the identi-
fication of prognostic factors of clinical response and re-
tention are of growing importance, as highlighted by the
2013 EULAR recommendations [8].
Conclusions
Abatacept retention rates at 6 and 12 months were
high and were consistent with previous studies in na-
tional registries. Anti-CCP positivity and less than
two prior anti-TNFs were predictors of higher abata-
cept retention. There are no contraindications or special
Fig. 3 Multivariate model of abatacept discontinuation (n = 834). Results are presented for variables retained in the model at the 10 % level. HRs
are presented with corresponding 95 % CIs. An HR >1 indicates an increased risk of abatacept discontinuation. An HR <1 indicates a decreased
risk of abatacept discontinuation. HRs are significant when the 95 % CIs do not overlap 1. The patient population included 17 patients who were
anti-TNF naïve and had previously received treatment with a biologic with a different mechanism of action. ACPA, anti-citrullinated protein
antibody; CI, confidence interval; HR, hazard ratio; TNF, tumor necrosis factor
(See figure on previous page.)
Fig. 2 Univariate model of abatacept discontinuation. Results are presented for variables retained in the model at the 20 % level. HRs are presented with
corresponding 95 % CIs. An HR >1 indicates an increased risk of abatacept discontinuation. An HR <1 indicates a decreased risk of abatacept
discontinuation. HRs are significant when the 95 % CIs do not overlap 1. The patient population included 17 patients who were anti-TNF naïve and who
had previously received treatment with a biologic with a different mechanism of action. CCP, cyclic citrullinated peptide; cDMARD,
conventional disease-modifying anti-rheumatic drug; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRP, C-reactive
protein; HR, hazard ratio; MTX, methotrexate; RF, rheumatoid factor; TNF, tumor necrosis factor
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warnings for abatacept in patients with cardiovascular co-
morbidities based on study results and registries, and the
results of this study suggest that abatacept may be a good
treatment option in these patients. Abatacept retention
varied between countries and may reflect differences in
healthcare systems. The prognostic factors described in
this study are derived from an international cohort of pa-
tients and may support therapy decisions made by physi-
cians when considering abatacept for the treatment of
moderate-to-severe RA. Further analyses on the complete
2-year dataset are expected to confirm these findings.
Overall, these findings indicate that abatacept may be a
treatment of choice in patients at high risk of disease
progression.
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